The American pharmaceutical Pfizer stops the development of an obesity pill that investors eagerly await. According to Bloomberg financial press agency, this is a hefty setback for Pfizer when it comes to competing with the popular weight -loss pricks of industryers Novo Nordisk and Eli Lilly.
Pfizer – which also has a large factory in our country in Puurs – says that his pill, called Danuglipron, caused liver damage to a patient during a study. The company has therefore decided not to continue with the means to the last test phase.
Pfizer has made a pivot of the market for obesity in his post-covid recovery plan. Now that the demand for coronavaccins and therapies is decreasing, the sale of slimming treatments is flourishing. Connoisseurs have indicated that around 2030 there may be $ 130 billion worldwide in that market.
Pfizer had previously had to stop the development of a variant of Danuglipron, which you had to take twice a day, after many test subjects became nauseous, had to vomit and, as a result, left the research. Months before that, the company had given up a different oral obesity medication because there were worrying liver effects during a test.
The company will continue to develop other obesity treatments. In addition, Pfizer will then focus on an earlier stage of obesity.